{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:16:22Z","timestamp":1762352182713},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T00:00:00Z","timestamp":1335484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s00520-012-1451-6","type":"journal-article","created":{"date-parts":[[2012,4,26]],"date-time":"2012-04-26T03:51:33Z","timestamp":1335412293000},"page":"1395-1404","source":"Crossref","is-referenced-by-count":19,"title":["Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm"],"prefix":"10.1007","volume":"20","author":[{"given":"Z.","family":"Reguiai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. B.","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bachmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Peuvrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bezier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chevelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Colin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Guimbaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mineur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Artru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Gornet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Samalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Bensadoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ychou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,27]]},"reference":[{"key":"1451_CR1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1610-0387.2005.05058.x","volume":"3","author":"S Segaert","year":"2005","unstructured":"Segaert S, Tabernero J, Chosidow O et al (2005) The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3:599\u2013606","journal-title":"J Dtsch Dermatol Ges"},{"key":"1451_CR2","first-page":"S22","volume":"21","author":"S Segaert","year":"2007","unstructured":"Segaert S, Van Cutsem E (2007) Clinical management of EGFRI dermatologic toxicities: the European perspective. Oncology (Williston Park) 21:S22\u2013S26","journal-title":"Oncology (Williston Park)"},{"key":"1451_CR3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3747\/co.v16i1.361","volume":"16","author":"B Melosky","year":"2009","unstructured":"Melosky B, Burkes R, Rayson D et al (2009) Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 16:14\u201324","journal-title":"Curr Oncol"},{"key":"1451_CR4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1188\/08.CJON.283-290","volume":"12","author":"B Eaby","year":"2008","unstructured":"Eaby B, Culkin A, Lacouture ME (2008) An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs 12:283\u2013290","journal-title":"Clin J Oncol Nurs"},{"key":"1451_CR5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","volume":"18","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Maitland ML, Segaert S et al (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18:509\u2013522","journal-title":"Support Care Cancer"},{"issue":"11 Suppl 5","key":"1451_CR6","first-page":"17","volume":"21","author":"ME Lacouture","year":"2007","unstructured":"Lacouture ME, Cotliar J, Mitchell EP (2007) Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology (Williston Park) 21(11 Suppl 5):17\u201321","journal-title":"Oncology (Williston Park)"},{"key":"1451_CR7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079\u20131095","journal-title":"Support Care Cancer"},{"key":"1451_CR8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00128071-200809050-00002","volume":"9","author":"M Duvic","year":"2008","unstructured":"Duvic M (2008) EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am J Clin Dermatol 9:285\u2013294","journal-title":"Am J Clin Dermatol"},{"key":"1451_CR9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","volume":"19","author":"J Bernier","year":"2008","unstructured":"Bernier J, Bonner J, Vermoken JB et al (2008) Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19:142\u2013149","journal-title":"Ann Oncol"},{"key":"1451_CR10","first-page":"26","volume":"20","author":"LP Fox","year":"2006","unstructured":"Fox LP (2006) Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology (Williston Park) 20:26\u201334","journal-title":"Oncology (Williston Park)"},{"key":"1451_CR11","first-page":"156","volume":"66","author":"C Gridelli","year":"2008","unstructured":"Gridelli C, Maione P, Amoroso D et al (2008) Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Hematol 66:156\u2013162","journal-title":"Crit Rev Hematol"},{"key":"1451_CR12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","volume":"56","author":"JC Hu","year":"2007","unstructured":"Hu JC, Sadeghi P, Pinter-Brown LC et al (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56:317\u2013326","journal-title":"J Am Acad Dermatol"},{"key":"1451_CR13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/annonc\/mdq387","volume":"22","author":"K Potthoff","year":"2011","unstructured":"Potthoff K, Hofheinz R, Hassel JC et al (2011) Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 22:524\u2013535","journal-title":"Ann Oncol"},{"key":"1451_CR14","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/JCO.2006.06.1143","volume":"24","author":"KJ Oishi","year":"2006","unstructured":"Oishi KJ, Garey JS, Burke BJ et al (2006) Managing cutaneous side effects associated with erlotinib in head and neck cancer and non small lung cancer patient. J Clin Oncol 24:18s (abstract 18538)","journal-title":"J Clin Oncol"},{"key":"1451_CR15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.gcb.2009.02.008","volume":"33","author":"O Bouch\u00e9","year":"2009","unstructured":"Bouch\u00e9 O, Scaglia E, Reguia\u00ef Z et al (2009) Bioth\u00e9rapies cibl\u00e9es en canc\u00e9rologie digestive: prise en charge de leurs effets secondaires. Gastroenterol Clin Biol 33:306\u2013322","journal-title":"Gastroenterol Clin Biol"},{"key":"1451_CR16","first-page":"1290","volume":"28","author":"M Tulder van","year":"2003","unstructured":"van Tulder M, Furlan A, Bombardier C et al (2003) Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine 28:1290\u20131299","journal-title":"Spine"},{"key":"1451_CR17","unstructured":"CEBM\u2014 http:\/\/www.cebm.net\/index.aspx?o=1025"},{"key":"1451_CR18","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351\u20131357","journal-title":"J Clin Oncol"},{"key":"1451_CR19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","volume":"13","author":"A Jatoi","year":"2008","unstructured":"Jatoi A, Rowland K, Sloan JA et al (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 13:847\u2013853","journal-title":"Cancer"},{"issue":"No 15_suppl","key":"1451_CR20","doi-asserted-by":"crossref","first-page":"A9019","DOI":"10.1200\/jco.2010.28.15_suppl.9019","volume":"28","author":"G Deplanque","year":"2010","unstructured":"Deplanque G, Chavaillon J, Vergnenegre A et al (2010) CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. J Clin Oncol 28(No 15_suppl):A9019","journal-title":"J Clin Oncol"},{"key":"1451_CR21","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"A Scope","year":"2007","unstructured":"Scope A, Agero AL, Dusza SW et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390\u20135396","journal-title":"J Clin Oncol"},{"key":"1451_CR22","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","volume":"13","author":"B Wacker","year":"2007","unstructured":"Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913\u20133921","journal-title":"Clin Cancer Res"},{"key":"1451_CR23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaad.2006.06.034","volume":"55","author":"P Matheis","year":"2006","unstructured":"Matheis P, Socinski MA, Burkhart C et al (2006) Treatment of gefitinib-associated folliculitis. J Am Acad Dermatol 55:710\u2013713","journal-title":"J Am Acad Dermatol"},{"key":"1451_CR24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000088502","volume":"211","author":"E Molinari","year":"2005","unstructured":"Molinari E, De Quatrebarbes J, Andr\u00e9 T et al (2005) Cetuximab-induced acne. Dermatology 211:330\u2013333","journal-title":"Dermatology"},{"key":"1451_CR25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1684\/ejd.2009.0650","volume":"19","author":"NM Noronha e Menezes de","year":"2009","unstructured":"de Noronha e Menezes NM, Lima R et al (2009) Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients. Eur J Dermatol 19:248\u2013251","journal-title":"Eur J Dermatol"},{"key":"1451_CR26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaad.2009.03.046","volume":"61","author":"A Scope","year":"2009","unstructured":"Scope A, Lieb JA, Dusza SW et al (2009) A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 61:614\u2013620","journal-title":"J Am Acad Dermatol"},{"key":"1451_CR27","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1634\/theoncologist.2010-0063","volume":"15","author":"I Amitay-Laish","year":"2010","unstructured":"Amitay-Laish I, David M, Stemmer SM (2010) Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Oncologist 15:1002\u20131008","journal-title":"Oncologist"},{"key":"1451_CR28","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1016\/j.jaad.2009.11.589","volume":"63","author":"T Vergou","year":"2010","unstructured":"Vergou T, Stratigos AJ, Karapanagiotou EM et al (2010) Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol 63:e56\u2013e58","journal-title":"J Am Acad Dermatol"},{"key":"1451_CR29","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/annonc\/mdi300","volume":"16","author":"O Bouch\u00e9","year":"2005","unstructured":"Bouch\u00e9 O, Brixi-Benmansour H, Bertin A et al (2005) Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 16:1711\u20131712","journal-title":"Ann Oncol"},{"key":"1451_CR30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMc1003937","volume":"363","author":"B Vincenzi","year":"2010","unstructured":"Vincenzi B, Tonini G, Santini D (2010) Aprepitant for erlotinib-induced pruritus. N Engl J Med 363:397\u2013398","journal-title":"N Engl J Med"},{"key":"1451_CR31","unstructured":"NCI Common Terminology Criteria for Adverse Events (CTCAE) v4. ctep.cancer.gov\/reporting\/ctc.html"},{"key":"1451_CR32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","volume":"72","author":"SL Boone","year":"2007","unstructured":"Boone SL, Rademaker A, Liu D et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152\u2013159","journal-title":"Oncology"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1451-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-012-1451-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1451-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T18:06:40Z","timestamp":1594058800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-012-1451-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,27]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1451"],"URL":"https:\/\/doi.org\/10.1007\/s00520-012-1451-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,27]]}}}